Stepanova, Maria

Extrahepatic manifestations of hepatitis C: A meta-analysis of prevalence, quality of life, and economic burden

Younossi, Z., Park, H., Henry, L., Adeyemi, A., & Stepanova, M. (2016) · Gastroenterology

Hepatitis C virus researchHealth Systems, Economic Evaluations, Quality of Life

Cited by 400

Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease

Younossi, Z. M., Paik, J. M., Stepanova, M., Ong, J., Alqahtani, S., & Henry, L. (2024) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 321

Effects of alcohol consumption and metabolic syndrome on mortality in patients with nonalcoholic and alcohol-related fatty liver disease

Younossi, Z. M., Stepanova, M., Ong, J., Yilmaz, Y., Duseja, A., Eguchi, Y., El Kassas, M., Castellanos-Fernandez, M., George, J., Jacobson, I. M., et al. (2019) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 172

Depression in patients with nonalcoholic fatty liver disease and chronic viral hepatitis B and C

Weinstein, A. A., Kallman Price, J., Stepanova, M., Poms, L. W., Fang, Y., Moon, J., Nader, F., & Younossi, Z. M. (2011) · Psychosomatics

Liver Disease Diagnosis and TreatmentHepatitis C virus research

Cited by 147

Carnisone Increases Efficiency of DOPA Therapy of Parkinson's Disease: A Pilot Study

Boldyrev, A., Fedorova, T., Stepanova, M., Dobrotvorskaya, I., Kozlova, E., Boldanova, N., Bagyeva, G., Ivanova-Smolenskaya, I., & Illarioshkin, S. (2008) · Rejuvenation Research

Biochemical effects in animalsParkinson's Disease Mechanisms and Treatments

Cited by 123

The association of histologic and noninvasive tests with adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis

Younossi, Z. M., Anstee, Q. M., Wai-Sun Wong, V., Trauner, M., Lawitz, E. J., Harrison, S. A., Camargo, M., Kersey, K., Subramanian, G. M., Myers, R. P., et al. (2021) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 118

A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease

Younossi, Z. M., Ong, J. P., Takahashi, H., Yilmaz, Y., Eguc`hi, Y., El Kassas, M., Buti, M., Diago, M., Zheng, M.-H., Fan, J.-G., et al. (2022) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 115

Development and validation of a primary sclerosing cholangitis–specific patient‐reported outcomes instrument: The PSC PRO

Younossi, Z. M., Afendy, A., Stepanova, M., Racila, A., Nader, F., Gomel, R., Safer, R., Lenderking, W. R., Skalicky, A., Kleinman, L., et al. (2018) · Hepatology

Liver Diseases and ImmunityInflammatory Bowel Disease

Cited by 48

Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C

Younossi, Z. M., Stepanova, M., Afendy, M., Lam, B. P., & Mishra, A. (2013) · Journal of Viral Hepatitis

Hepatitis C virus researchHelicobacter pylori-related gastroenterology studies

Cited by 42

Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)

Golabi, P., Stepanova, M., Pham, H. T., Cable, R., Rafiq, N., Bush, H., Gogoll, T., & Younossi, Z. M. (2018) · BMJ Open Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 32

Factors Associated With Potential Progressive Course of Primary Biliary Cholangitis: Data From Real-world US Database

Younossi, Z. M., Stepanova, M., Golabi, P., Epstein, R. S., Strauss, M. E., Nader, F., & Racila, A. (2019) · Journal of Clinical Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 18